Sensitivity analysis revealed that the pharmacist intervention
may be cost saving for terminal patients. These
results raise the hypothesis that clinical pharmacist
interventions could be cost-effective for subgroups of
patients, for example, those who cost most. Indeed,
interventions targeting such patients may have great
implications on healthcare costs; the majority of
healthcare resources are spent on a small proportion of
all patients,23 a fact that is also illustrated by the skewed
distribution of costs in the present study.